請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34383
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
dc.contributor.author | Chih-Feng Wu | en |
dc.contributor.author | 吳志峰 | zh_TW |
dc.date.accessioned | 2021-06-13T06:05:51Z | - |
dc.date.available | 2007-07-31 | |
dc.date.copyright | 2006-07-31 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-06-14 | |
dc.identifier.citation | 1. Globocan 2002, IARC. Available from URL: http://www-dep.iarc.fr/.
2. Robinson WS. Hepatitis D virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Disease. 4th ed. New York: Churchill Livingstone; 1995:1406-1439. 3. Center for disease control, R.O.C. (Taiwan). Available from URL: http://www.cdc.gov.tw/index_info_info.asp?data_id=1343. 4. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15 Suppl:E3-6. 5. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993;262:369-370. 6. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745. 7. IARC. Hepatitis viruses. IARC Monographs on the evaluation of carcinogenic risks to humans, vol. 59. Lyon: IARC Scientific Publications, International Agency for Research on Cancer, 1994. 8. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997;6:387-400. 9. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, Hsiao TJ, Lee PH, Chen CJ. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92:1159-1164. 10. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002;2:43-50. 11. Bonino F, Hoyer B, Nelson J, Engle R, Verme G, Gerin J. Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver. Hepatology 1981;1:386-391. 12. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174. 13. Tang B, Kruger WD, Chen G, Shen F, Lin WY, Mboup S, London WT, Evans AA. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol 2004;72:35-40. 14. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265-272. 15. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. 16. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-650. 17. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-559. 18. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002;40:1207-1209. 19. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002;17:165-170. 20. Yuen MF, Sablon E, Yuan HJ, Wong DK, Hui CK, Wong BC, Chan AO, Lai CL. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003;37:562-567. 21. Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, Sung JJ. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53:1494-1498. 22. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method. J Infect Dis 1997;175:1285-1293. 23. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122:1756-1762. 24. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999;179:775-782. 25. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 2000;7:258-267. 26. Loeb KR, Jerome KR, Goddard J, Huang M, Cent A, Corey L. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 2000;32:626-629. 27. Ryncarz AJ, Goddard J, Wald A, Huang ML, Roizman B, Corey L. Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol 1999;37:1941-1947. 28. Kirschberg O, Schuttler C, Repp R, Schaefer S. A multiplex-PCR to identify hepatitis B virus--Genotypes A-F. J Clin Virol 2004;29:39-43. 29. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999;52:1165-1172. 30. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994;50:1064-1072. 31. Cleveland WS. Robust Locally Weighted Regression and Smoothing Scatterplots. J Am Stat Assoc 1979;74:829-836. 32. Cleveland WS, Grosse E. Computational methods for local regression. Statistics and computing 1991;1:47-62. 33. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-181. 34. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 1983;3:656-662. 35. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-1241. 36. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-270. 37. Liaw YF, Chu CM, Lin DY, Sheen IS, Yang CY, Huang MJ. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984;13:385-391. 38. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-1415. 39. Ikeda K, Arase Y, Kobayashi M, Someya T, Saitoh S, Suzuki Y, Suzuki F, Tsubota A, Akuta N, Kumada H. Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients. Intervirology 2003;46:96-104. 40. Evans AA, O'Connell AP, Pugh JC, Mason WS, Shen FM, Chen GC, Lin WY, Dia A, M'Boup S, Drame B, London WT. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 1998;7:559-565. 41. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010. 42. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020. 43. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34383 | - |
dc.description.abstract | 背景: B型肝炎病毒量已被報告和肝細胞癌的危險性有關。本研究主要有三個目的: 1) 探討B型肝炎病毒量的長期變化趨勢; 2) 評估B型肝炎基因型和其它因子對於病毒量循跡現象的影響; 以及3)研究B型肝炎病毒量的長期變化趨勢與肝細胞癌危險性的關係。方法: 以1989-1992年收案的男性B型肝炎帶原者世代為基礎進行病例-世代研究。經過16年的追蹤,共有112位肝細胞癌患者發生,連同1031位健康帶原者,一共納入7706個時點的血液檢體。B型肝炎病毒量和基因型是利用以聚合酵素鏈鎖反應為原理的方法測量。我們使用weighted Cox’s proportional hazards model和廣義線性混合模型分別探討病毒因子和肝細胞癌的關係,以及B型肝炎病毒量的循跡現象。結果: 帶有基因型C者比帶有基因型B者具有較高的病毒量 (P值<0.001),而且B型肝炎病毒的基因型會影響病毒量隨年齡的變化趨勢 (年齡與基因型之交乘項的P值<0.001)。在16年的追蹤期間,B型肝炎病毒量呈現相當良好的循跡現象,在基線時所測得的病毒量對於16年以內的病毒量測量值有很高的預測力。肝細胞癌的危險性會隨著病毒量持續處於危險值 (>4.386 log10 copies/mL)的時間越長而越高。持續3、6和9年的多變項調整之危險比分別為:5.00 (95%信賴區間:2.73-9.16),6.71 (95%信賴區間:3.07-14.67),和9.17 (95%信賴區間:2.59 -32.48)。結論: 經過長期的追蹤評估,B型肝炎病毒量具有良好的循跡現象。病毒量持續處於危險值以上的時間長短和肝細胞癌的危險性呈現正相關。我們建議30歲以上、病毒量處於活躍複製時期的B型肝炎帶原者,應及早接受介入治療。 | zh_TW |
dc.description.abstract | Background: Hepatitis B viral load measured in terms of circulating hepatitis B virus (HBV) DNA levels has been associated with hepatocellular carcinoma (HCC) risk. The specific aims of this study were threefold: 1) to explore the long-term patterns of HBV viral load; 2) to assess the influence of HBV genotype and other factors on the tracking of HBV viral load over time; and 3) to examine the long-term patterns of HBV viral load and subsequent risk of developing HCC after adjusting for viral genotype. Methods: A case-cohort study was conducted within a cohort of male HBV carriers whose initial blood samples were taken in 1989-1992. We used PCR-based assays to determine HBV viral load and genotype on 7706 plasma samples, collected during a period of up to 16 years of follow-up, from a total of 112 individuals who subsequently developed HCC and 1031 unaffected individuals. A weighted Cox’s proportional hazards model was used to assess the association between viral factors and HCC. We evaluated tracking of HBV viral load using the generalized linear mixed model. Results: Carriers of genotype C HBV had a significantly higher HBV viral load than carriers of genotype B HBV (P < 0.001). HBV genotype influenced the decreasing trend of viral load with age (P for age×genotype interaction < 0.001). Over a period of 16 years, both stability coefficients and tracking for subjects at risk for HBV viral load were high, indicating high predictability of initial measurements for values within 16 years. The HCC risk increased with increasing duration of having at-risk viral load, defined as ≥ 4.386 log10 copies/mL, showing adjusted hazard ratios were 5.00 (95% confidence interval [CI] = 2.73 to 9.16), 6.71 (95% CI = 3.07 to 14.67), 9.17 (95% CI = 2.59 to 32.48), respectively, for duration of persistence within 3, 6, 9 years of the initial measurement. Conclusions: Tracking of HBV viral load after long-term follow-up was high. Duration of persistence for having at-risk viral load was positively associated risk of HCC. Our data recommend that the prophylactic intervention for active viral infection should be at earlier ages among HBV carriers aged 30 years or older. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:05:51Z (GMT). No. of bitstreams: 1 ntu-95-R93842011-1.pdf: 2049699 bytes, checksum: 76f646a2c52612aaf0320332185491f8 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 1.中文摘要-------------------------------------------------------------------------------------3
2.Abstract--------------------------------------------------------------------------------------4 3.Introduction-------------------------------------------------------------------------------6 4.Materials and Methods------------------------------------------------------------------8 5.Results---------------------------------------------------------------------------------------14 6.Discussion-----------------------------------------------------------------------------------17 7.Reference------------------------------------------------------------------------------------21 8.Appendix------------------------------------------------------------------------------------27 | |
dc.language.iso | en | |
dc.title | B型肝炎病毒量的長期變化趨勢和肝細胞癌的危險性:病例世代研究 | zh_TW |
dc.title | Long-Term Patterns of Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma: A Case-Cohort Study | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳培哲,蕭朱杏,陳振陽,葉昭廷 | |
dc.subject.keyword | B型肝炎病毒,B型肝炎病毒量,病例世代研究,重覆性測量,循跡分析,B型肝炎病毒之基因型, | zh_TW |
dc.subject.keyword | HBV,HBV viral load,case-cohort study,repeated measurements,tracking analysis,HBV genotype, | en |
dc.relation.page | 37 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-06-14 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 2 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。